Takeda’s subcutaneous formulation of Entyvio smashes primary endpoint in Crohn’s disease
pharmafile | July 23, 2019 | News story | Manufacturing and Production, Research and Development | Crohn’s disease, Entyvio, Takeda, crohn’s disease, pharma
Takeda has unveiled new Phase 3 data for a subcutaneous formulation of its gut-selective biologic Entyvio (vedolizumab), showing that the therapy met its primary endpoint as a maintenance treatment for moderately to severely active Crohn’s disease (CD).
The data was drawn from 644 trial participants who had not responded or responded inadequately to corticosteroids, immunomodulators, or tumor necrosis factor-alpha (TNFα)-antagonist therapy prior to enrolment. Patients were given the subcutaneous formulation of Takeda’s therapy at the beginning of week six, every two weeks until week 50.
The findings relate specifically to CD in adult patients who achieved clinical response at week six after receiving two doses of open-label vedolizumab intravenous (IV) therapy at weeks 0 and 2.
It was found that a “statistically significant” proportion of participants achieved clinical remission with Entyvio after 52 weeks of treatment compared to placebo, meeting the trial’s primary endpoint, while the therapy’s safety profile was found to be consistent with previous studies.
“Meeting the primary endpoint of the VISIBLE 2 study marks a crucial step in our efforts to help patients with Crohn’s disease as to how they may receive treatment with vedolizumab, whether that is intravenously or subcutaneously,” said Dr Asit Parikh, Head of Takeda’s Gastroenterology Therapeutic Area Unit. “These data, alongside the pivotal VISIBLE 1 results in ulcerative colitis, provide a more comprehensive picture of the new investigational subcutaneous formulation of vedolizumab as maintenance therapy for both ulcerative colitis and Crohn’s disease.”
Matt Fellows
Related Content
Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …
